Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer

On November 9, 2026 Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, reported topline clinical data from its Phase 2 trial (FTH-PIK-201; NCT06463028; GOG-3111) of PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib, given with paclitaxel to patients with advanced endometrioid endometrial cancer and a PI3K/AKT/mTOR (PAM) pathway mutation who had received at least one prior line of therapy. The trial is being conducted in collaboration with The GOG Foundation, Inc. (GOG-F).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This press release features multimedia. View the full release here: View Source

The Phase 2 trial is ongoing, and the topline data include 42 patients with endometrioid endometrial cancer who had a median of 2 prior lines of therapy (range 1-4 lines). As of the October 30, 2026 efficacy data cut, confirmed objective responses were observed in 12 of the 36 efficacy-evaluable patients, for a confirmed objective response rate (ORR) of 33%. One additional patient had a partial response that could not be confirmed because the patient discontinued the study before a confirmatory scan, for an unconfirmed ORR of 36% (13 of 36). Among patients with a PIK3CA mutation, the confirmed ORR was 44% (7 of 16). In the 42 treated patients, the preliminary Kaplan-Meier estimated median progression-free survival (PFS) was 7.4 months (95% CI 5.3-NR), and the 6-month PFS rate was 62% (95% CI 43%-75%); 16 patients remained on treatment at the data cut.

"We believe these data support the multi-nodal PAM targeting hypothesis, whereby more complete inhibition of the pathway may drive durable responses and extend progression-free survival without the safety limitations of single-node inhibitors," said Anand Parikh, Co-Founder and Chief Executive Officer of Faeth. "Endometrial cancer has among the highest rates of PI3K pathway alterations of any cancer, yet no drug that targets the pathway is approved to treat it.

"In PIK-201, PIKTOR delivered a preliminary estimated median PFS of 7.4 months, which we believe compares favorably to the 3-4 months typical for salvage chemotherapy alone, or the 6-7 months observed with newer treatments including TOPO1-based ADCs." Mr. Parikh continued, "In our view, these preliminary data set PIKTOR apart. On the safety side, hyperglycemia and stomatitis were mostly low grade in a population in which nearly half of patients had diabetes or prediabetes and prophylactic steroid mouthwash was not required. We now plan to advance toward a Phase 3 trial, subject to regulatory alignment, with the goal of getting PIKTOR into the hands of patients as expeditiously as possible."

"We need more treatment options for patients whose advanced endometrial cancer has progressed after platinum chemotherapy and immunotherapy," said David Starks, MD, MPH, a PIK-201 and GOG Foundation principal investigator and Gynecologic Oncologist at Avera Cancer Institute, Sioux Falls, South Dakota. "I believe the response and progression-free survival data reported for PIKTOR with paclitaxel give physicians a reason to follow it closely. I am excited by the potential that this treatment could have for my patients."

Phase 2 FTH-PIK-201 Topline Clinical Data Highlights

Baseline characteristics

The open-label, single-arm Phase 2 trial (NCT06463028, GOG-3111) is evaluating patients with PIKTOR plus paclitaxel.
48% of patients had diabetes or pre-diabetes at baseline.
76% of patients had distant metastases, including liver and lung lesions.
Patients had a median of 2 prior lines of therapy (range 1 to 4), with 3 or more prior lines in 15 patients (36%).
All patients had been previously treated with taxane-based chemotherapy (100%), and prior immunotherapy was reported in 41 patients (98%).
Of the 42 treated patients, 6 were not evaluable for efficacy, having discontinued prior to the first post-baseline scan due to early disease progression (n=3) or non-treatment-related reasons (n=3).
Efficacy

As of the October 30, 2026 efficacy data cut:

The confirmed ORR was 33% (12 of 36 efficacy-evaluable patients). One additional patient had a partial response that could not be confirmed because the patient discontinued the study before a confirmatory scan, for an unconfirmed ORR of 36% (13 of 36).
Among patients with a PIK3CA mutation, the confirmed ORR was 44% (7 of 16).
At the data cut, 9 of the 12 confirmed responders and 7 patients with a best response of stable disease remained on treatment. Several responses deepened over the course of therapy, including one patient who converted from stable disease to partial response after 20 months of treatment.
The disease control rate (DCR) was 83% (30 of 36), defined as the percentage of patients with a best overall response of complete response, partial response or stable disease.
In all 42 treated patients, the preliminary Kaplan-Meier estimated median PFS was 7.4 months (95% CI: 5.3 to NR), and the preliminary 6-month PFS rate was 62% (95% CI: 43% to 75%).
Safety

As of the October 23, 2026 safety data cut:

Two patients (5%) discontinued treatment due to a treatment-related adverse event (TRAE; headache, dizziness). There were no treatment-related deaths.
64% of patients had a grade 3 or higher TRAE. Neutropenia, a grouped term including neutropenia and decreased neutrophil count, occurred in 36% of patients overall and was the most frequent grade 3 or higher TRAE (26%).
Hyperglycemia TRAEs occurred in 5 of 42 patients (12%), and 1 patient (2%) had a grade 3 event. 48% of patients had diabetes or pre-diabetes at baseline.
Stomatitis TRAEs occurred in 21% of patients, and 1 patient (2%) had a grade 3 event. Patients did not receive steroid mouthwash prophylaxis.
Webcast details

Faeth will host a webcast today, November 9, 2026, at 8:00 a.m. ET to discuss the data. David Starks, MD, MPH, Gynecologic Oncologist at Avera Cancer Institute, Sioux Falls, South Dakota, will join management. To access the live webcast, click here. A replay will be available in the Events and Presentations (Events and Presentations — Faeth Therapeutics, Inc) section of Faeth’s corporate website.

(Press release, Faeth Therapeutics, NOV 9, 2026, View Source [SID1234674503])

Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results

On November 9, 2026 Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, reported financial results for the third quarter ended September 30, 2026 and provided a summary of recent business highlights. The Company has elected not to host a third quarter earnings conference call after release of its financial results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are entering the next phase of Zymeworks growth with a fundamentally stronger and more diversified business. The transformation of Zymeworks is becoming increasingly visible in our financial profile and in the breadth of opportunities available to us," said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. "Over the course of 2026, Ziihera has expanded its label into first-line HER2-positive advanced gastroesophageal adenocarcinoma, we have completed the acquisition of Theravance Biopharma, adding a recurring commercial cash-flow stream through YUPELRI. We have also made progress on strategic transactions that can expand the opportunities for our R&D portfolio, while reducing risk, maintaining R&D discipline, and adding potential future milestones and royalties. We are pleased to report an increase in our financial guidance for 2026 as a result of this business development execution. These advancements demonstrate the strategy we set out a year ago – to build a durable financial foundation through partnered and commercial assets, while maintaining the ability to create additional value through R&D, acquisitions, partnerships and disciplined capital allocation."

Financial Highlights

Royalty revenue from Jazz Pharmaceuticals (Jazz) and BeOne Medicines (BeOne) was $2.3 million in the three months ended September 30, 2026, driven primarily by net product sales of Ziihera by Jazz in the United States.
YUPELRI collaboration revenue increased 4% year-over-year (YoY). Quarterly U.S. net sales of $71.5 million for YUPELRI, recognized by Viatris, in 3Q-2026, increasing 0.2% YoY (3Q-2026 vs 3Q-2025).
Increased doses of YUPELRI pulled through the hospital channel grew at a double-digit rate YoY, reflecting continued underlying momentum. Theravance Biopharma contributed approximately $1.5 million of revenue during the quarter, reflecting seven days of ownership following the September 23, 2026 acquisition date.
Under the terms of our collaboration with Jazz, Zymeworks received a $250 million milestone payment related to Ziihera’s U.S. FDA approval for first-line treatment of HER2-positive advanced GEA in October 2026. Zymeworks remains eligible for up to $190 million in potential additional global regulatory milestones related to ex-U.S. approvals for Ziihera in HER2-positive GEA from Jazz and BeOne.
During 2026, Zymeworks has accessed $600 million of non-dilutive financing through a non-recourse royalty-backed note, and a non-recourse note, with a weighted average cost of capital of less than 10%. The financing supported the Theravance Biopharma acquisition and the Company’s share repurchase program while minimizing equity dilution. The Company currently has no current plans for additional equity issuances.
Repurchased 534,381 shares for $14.0 million in the third quarter of 2026, with total share repurchases of 5,737,790 shares for $140.4 million in the first nine months of 2026 at an average price of $24.48 per share (exclusive of commission expense and estimated excise tax).
The Company has increased its 2026 financial guidance for total revenue to be between $337 million and $351 million (previously between $278 million and $292 million) and adjusted EBITDA to be between $176 million and $190 million (previously between $114 million and $128 million), excluding the impact of any future transactions. This financial guidance is subject to expiration or termination of the waiting period under HSR as it relates to the Roche collaboration, expected during the fourth quarter of 2026.

Business Highlights

Expanding Revenue Diversification Through Theravance Biopharma Acquisition

On September 23, 2026, Zymeworks completed the previously announced acquisition of Theravance Biopharma. With the completion of the transaction, Theravance Biopharma is now part of Zymeworks, further advancing Zymeworks’ strategy to build a diversified revenue-generating biotechnology company, combining innovative R&D with growing commercial and royalty-based cash flows. Post-closing, we expect $13 million to $15 million of annualized overhead and corporate costs to be eliminated, reducing future operating expenses.
On September 28, 2026, Zymeworks announced the appointment of Stuart Knight as Executive Vice President, Chief Information Officer, as well as Jesse Fecker as Vice President of Intellectual Property, both of whom join Zymeworks from Theravance Biopharma.
On October 19, 2026, Zymeworks announced the appointment of Suzanne Monahan as Senior Vice President and General Manager, Theravance Biopharma.

Recent Developments

Recent key developments related to our portfolio are discussed below:

Ziihera (zanidatamab-hrii)

On August 25, 2026, our partner Jazz received U.S. FDA approval for two Ziihera-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive GEA. Jazz subsequently launched U.S. commercialization, and secured a recommendation in the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Clinical Practice Guidelines, as well as a Category 2A recommendation from the National Comprehensive Cancer Network (NCCN), positioning Ziihera as a preferred treatment for first-line GEA patients.
On October 23, 2026, results from the second interim, and final formal, analysis of HERIZON-GEA-01 were presented as a late-breaking rapid oral presentation at the ESMO (Free ESMO Whitepaper) Annual Congress 2026. Key findings include:
Nearly 40% of patients alive at three years with Ziihera plus tislelizumab and chemotherapy, irrespective of PD-L1 status, achieving a median overall survival (OS) of 27 months.
Mature HERIZON-GEA-01 results show Ziihera plus chemotherapy delivered statistically significant and clinically meaningful OS benefit, reducing the rate of death by 24% versus trastuzumab plus chemotherapy.
The Ziihera plus tislelizumab and chemotherapy regimen reduced the risk of death by 35% (hazard ratio [HR] 0.65; 95% CI: 0.52–0.80), improving from an HR of 0.72 at the first interim analysis.

Other Partnered Programs

ZW209

On October 23, 2026, Zymeworks announced an exclusive global collaboration and license agreement with Roche for the development of ZW209. Under the agreement, Zymeworks is eligible to receive an upfront payment of $55 million, a $40 million payment upon initiation of the Phase 1b trial, additional development, commercial and sales-based milestone payments of up to $718 million, and tiered high single digit to mid-teens royalties on future net sales of any approved medicines resulting from the collaboration. This transaction is subject to the expiration or termination of the waiting period under HSR.
ZW209 has received Investigational New Drug clearance from the U.S. FDA. We anticipate initiating a Phase 1, open-label, multicenter, global study in 2026 investigating ZW209 in collaboration with Roche to evaluate safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity. Roche will fund the Phase 1a trial and be responsible for subsequent global development and commercialization of ZW209.

"Importantly, this collaboration with Roche demonstrates how the components of our business model work together in practice. By combining recurring commercial cash flows with a disciplined approach to R&D and partnerships, we are building a business model that can generate value through multiple pathways," said Kenneth Galbraith. "Recurring cash flows provide greater flexibility to invest selectively in programs and opportunities with meaningful value-creation potential, while our R&D engine and business development activities create additional opportunities to generate milestones, royalties, licensing proceeds and other sources of long-term value. Just as importantly, we can increasingly match the capital and ownership structure to each opportunity, whether acquiring and operating a business, partnering an asset, licensing a program or bringing in external venture capital, without assuming that every opportunity must be funded entirely from our balance sheet."

Pasritamig

On November 7, 2026, our partner Johnson & Johnson presented new data on the Phase 1 study of pasritamig (KLK2×CD3) in combination with JNJ-9401 (PSMA×CD28) at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper). Results demonstrated encouraging anti-tumor activity in heavily pretreated patients with metastatic castration-resistant prostate cancer:

At the recommended Phase 2 regimen, the combination achieved a 73% PSA50 response rate, 47% PSA90 response rate, and undetectable PSA in 27% of patients, with responses ongoing beyond six months in all four patients achieving undetectable PSA.
The combination maintained a favorable safety profile, with no Grade ≥3 treatment-related adverse events, no Grade ≥2 CRS and no treatment discontinuations at the recommended regimen.

Wholly-Owned R&D Pipeline

On October 24, 2026, Zymeworks presented new Phase 1 data for folate receptor alpha-targeting antibody-drug conjugate, ZW191, at the ESMO (Free ESMO Whitepaper) Annual Congress. Updated data presented for ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor alpha expression levels:
Confirmed objective response rates of 64.5% at the 6.4 mg/kg dose in patients with high-grade serous platinum-resistant ovarian cancer.
Median duration of response not yet reached at either dose level at median 7 months follow-up, with six-month progression-free survival rate of 61% in both groups.
Favorable tolerability profile, particularly at 6.4 mg/kg, supports continued clinical development in partnership or through a strategic collaboration.
On November 7, 2026, Zymeworks presented preclinical data at SITC (Free SITC Whitepaper) on a novel PD-1xVEGFxIL-7 multispecific antibody with optimized geometry that achieves targeting of IL-7 to PD-1+ T cells. The poster presentation titled "Engineering targeted IL-7 delivery to enhance anti-tumor T cell fitness and persistence" shows that combining checkpoint and angiogenesis blockade with a T cell cytokine signal, PD-1xVEGFxIL-7 represents a mechanistically distinct strategy to improve the durability of anti-tumor responses.
On December 13, 2026, Zymeworks will present new preclinical data for a penta-specific antibody at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exhibition via a poster presentation titled "ZW1953: A multispecific T cell engager targeting FLT3, CLEC12A, and CD33 with conditional CD28 co-stimulation designed to overcome resistance mechanisms and improve treatment responses in AML", representing the first scientific disclosure for Zymeworks in a hematological cancer indication.

The Company plans to host a R&D Day on February 11th, 2027 in New York, NY. A live webcast of the event will be accessible through Zymeworks’ Investor Relations website at ir.zymeworks.com. A detailed agenda, including registration and dial-in information, will be provided closer to the event.

Financial Results for the Quarter Ended September 30, 2026

The key financial highlights for our 2026 third quarter results are as follows:

Theravance Biopharma Acquisition – The acquisition of Theravance Biopharma closed on September 23, 2026 and had a limited impact on third quarter operating results given the timing of the transaction. Theravance Biopharma contributed approximately $1.5 million of revenue during the quarter, reflecting seven days of ownership following the acquisition date. The primary earnings impact related to integration and transaction-related costs associated with the acquisition.

Revenue – Total revenue was $256.5 million in 3Q-2026, compared to $27.6 million for the same period in 2025. The increase was primarily due to the $250.0 million milestone earned from Jazz following the U.S. approval of Ziihera for first-line HER2-positive GEA in August 2026. The increase was partially offset by the absence of a $25.0 million development milestone from Johnson & Johnson Innovative Medicine recognized during the third quarter of 2025.

Research and Development (R&D) Expenses – R&D expenses were $36.1 million in 3Q-2026, compared to $35.6 million for the same period in 2025. R&D expenses were generally consistent with the prior year period, as lower spending on ZW171 following discontinuation of the program in 2025 and reduced spending on certain preclinical programs after completion of IND-enabling activities were largely offset by employee-related costs associated with the Theravance Biopharma acquisition.

Selling, General and Administrative (SG&A) Expenses – SG&A expenses were $42.7 million in 3Q-2026, compared to $14.1 million for the same period in 2025. The increase was primarily driven by costs associated with the Theravance Biopharma acquisition, including severance and transaction-related professional fees, together with higher stock-based compensation expense associated with 2026 equity awards, including leadership transition awards and the settlement of certain Theravance Biopharma equity awards.

Other Income, net – Net other expense was $4.4 million in 3Q-2026, compared to net other income of $3.8 million for the same period in 2025. The change was driven primarily by interest expense related to the royalty-backed note financing arrangement with Royalty Pharma executed in March 2026 and lower interest income resulting from reduced investment balances.

Net Loss – Net income was $173.7 million in 3Q-2026, compared to a net loss of $19.6 million for the same period in 2025. The increase was driven primarily by the $250.0 million milestone earned from Jazz following U.S. approval of Ziihera for first-line HER2-positive GEA in August 2026, partially offset by nonrecurring acquisition related costs and interest expense associated with the Company’s royalty-based note financing arrangement with Royalty Pharma in March 2026.

Since initiating its share repurchase program in August 2024, the Company has cumulatively utilized $279.8 million to reacquire 12,940,827 shares at an average price of $21.63 per share (exclusive of commission expense and estimated excise tax). As of November 6, 2026, the Company had approximately 69.0 million common shares outstanding.

(Press release, Zymeworks, NOV 9, 2026, View Source [SID1234674519])

Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights

On November 9, 2026 Aura Biosciences, Inc. (NASDAQ: AURA) ("Aura" or the "Company") a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, reported financial results for the third quarter ended September 30, 2026, and provided a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"During the third quarter, we continued to execute against our focused ocular oncology strategy and build the operational capabilities needed for our next stage of development," said Natalie Holles, Chief Executive Officer of Aura Biosciences. "With all treatment visits completed in the CoMpass trial, our team is focused on ensuring excellence in all elements of the bel-sar program as we advance toward topline pivotal data in the second half of next year and position bel-sar as the first potential vision-preserving front-line therapy for early choroidal melanoma."

Recent Business Highlights

Phase 3 CoMpass Trial in Early Choroidal Melanoma

Enrollment is complete with 108 participants in the Phase 3 CoMpass trial of belzupacap sarotalocan (bel-sar) for the treatment of early choroidal melanoma, the most common primary tumor of the eye which carries an approximately 50% risk of advancing to metastatic disease. As of the third quarter of 2026, all participants have completed their treatment regimen and are in the 24-month follow-up observation period. The trial is on track to deliver topline data from the 15-month primary endpoint in the second half of 2027.

The trial is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). The SPA represents alignment with the FDA on the trial design and planned analyses to support a potential Biologics License Application (BLA) of bel-sar. If successful, bel-sar would be the first approved front-line vision-preserving therapy for patients with early choroidal melanoma, providing a meaningful new treatment option where no FDA-approved drug therapies currently exist.

Additional Ocular Oncology Programs

Aura continues to advance the development of bel-sar in metastases to the choroid and cancers of the ocular surface in ongoing early clinical trials. In the first quarter of 2027, Aura expects to provide an update on both programs, including details on disease burden, trial design, and timelines to future data read-outs from these studies.

Operational Updates

During the quarter, Aura established a new supply relationship with an industry-leading contract development and manufacturing organization (CDMO) with extensive commercial experience in the manufacture of viral vector-based medicinal products. In a key element of the relationship, Aura and its CDMO partner are establishing manufacturing capacity which will be designated for bel-sar development and commercial supply production.

"We are very pleased to enter this new CDMO relationship, which we believe positions bel-sar for regulatory and commercial success as we advance toward topline data and completion of the CoMpass study," said Susan Abu-Absi, Ph.D., Chief Operating Officer of Aura Biosciences. "Designated capacity is intended to provide us with long-term control over our production scheduling, and we look forward to working with our new partner to advance this important element of the bel-sar program."

Upcoming Events

Aura will host an early choroidal melanoma investor and analyst virtual event on Tuesday, December 8, 2026, from 7:30-9:00 a.m. ET. Members of Aura’s management team will be joined by key opinion leader, Dr. Arun Singh, Director of the Department of Ophthalmic Oncology in the Cole Eye Institute of the Cleveland Clinic. The event will address the current treatment paradigm and unmet need, and an updated analysis of the epidemiology of early choroidal melanoma. To register for the virtual event, click here.

Aura also announced that Natalie Holles, Chief Executive Officer and President, will participate in the following upcoming investor conferences in the fourth quarter of 2026:

•
Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026.
o
Fireside chat at 2:40 p.m. ET
•
9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026.
o
Fireside chat at 2:10 p.m. ET

The live webcast of the events will be available on the "Investors & Media" page under the "Events & Presentations" section of the Company’s website at View Source, where a replay of the webcasts will be archived for 90 days following the presentation date.

Third Quarter 2026 Financial Results

•
As of September 30, 2026, Aura had cash and cash equivalents and marketable securities totaling $297.2 million. The Company believes its current cash and cash equivalents and marketable securities are sufficient to fund its operations into the first half of 2029.

•
Research and development expenses increased to $24.7 million for the three months ended September 30, 2026 from $22.2 million for the three months ended September 30, 2025, primarily due to ongoing clinical and contract research organization (CRO) costs associated with the progression of the global Phase 3 CoMpass trial of bel-sar in early choroidal melanoma.

•
General and administrative expenses increased to $10.3 million for the three months ended September 30, 2026 from $5.7 million for the three months ended September 30, 2025. General and administrative expenses include $2.8 million and $1.7 million of stock-based compensation for the three months ended September 30, 2026 and 2025, respectively. The increase was primarily driven by restructuring charges recognized in accordance with the Company’s organizational restructuring during the third quarter of 2026.

•
Net loss for the three months ended September 30, 2026 was $32.1 million compared to $26.1 million for the three months ended September 30, 2025.

•
In connection with the Company’s organizational restructuring to align resources behind its ocular oncology portfolio, the Company incurred restructuring charges of approximately $4.5 million, comprised of employee termination benefits which include severance, continuation of health care benefits, and outplacement services as well as incremental stock-based compensation expense resulting from the acceleration of vesting of certain stock-based awards. The restructuring plan was completed in the third quarter of 2026.

(Press release, Aura Biosciences, NOV 9, 2026, View Source [SID1234674464])

Biodexa provides R&D Update

On November 9, 2026 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) ("Biodexa" or "the Company"), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers reported further progress in both its lead programs; eRapa for familial adenomatous polyposis ("FAP") and MTX240 molecular glue for gastrointestinal stromal tumors ("GIST").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Commenting, Stephen Stamp, Chief Executive Officer of Biodexa said "Database lock and topline data for our registrational FAP trial around the end of next year is now tantalizingly close. Also, around the same time, we should know whether we have a viable dose for MTX240 in TKI-resistant patients. If we do, MTX240 has the potential to alter standard of care for all GIST patients ".

eRapa for FAP
The Company has enrolled 112 of an expected 168 participants in its registrational Phase 3 trial of eRapa, the Company’s reformulation of rapamycin, in FAP (NCT06950385). The trial, branded "Serenta" is recruiting at 29 clinical sites across the US and five countries in Europe with further sites in North America and Continental Europe expected to be initiated shortly.

The Serenta protocol provides for a pre-specified futility analysis after 25 progression free survival ("PFS") events and database lock after 75 PFS events. The Serenta protocol includes a composite endpoint which defines the nature of the PFS events. Based on the current rate of PFS event accrual, the futility analysis could take place early in 2027 with database lock potentially occurring around the end of 2027, both significantly sooner than originally anticipated.

MTX240 molecular glue for GIST

Non-resectable and/or metastatic GIST is generally treated with tyrosine kinase inhibitors ("TKIs"). While TKIs have improved outcomes, resistance almost always develops through either secondary (or tertiary) KIT or PDGFR mutations or activation of alternative signalling pathways resulting in limited therapeutic options for patients once they have cycled through the available TKIs. In multiple patient-derived xenograft models, MTX240 has been shown to be effective in TKI-resistant GIST tumors1.

The Company is planning a Phase 1a dose escalation study followed immediately by a Phase 1b dose optimization study with a view to establishing a maximum tolerated dose and, based on efficacy signals, an optimized dose for MTX240. Both Phase 1a and 1b will recruit patients who have demonstrated TKI-resistance. GMP drug substance has been manufactured by our CDMO partner and they are moving ahead with GMP finished product. A preferred CRO has been identified and the Phase 1a is expected to begin recruiting in South Korea mid-2027. A pre-IND meeting with the FDA is scheduled for December 10, 2026.

(Press release, Biodexa Pharmaceuticals, NOV 9, 2026, View Source [SID1234674480])

Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC

On November 9, 2026 Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, reported it will host a webcast for investors to present updated results from its ongoing Phase 2 trial of silevertinib in frontline patients with EGFR mutated non-small cell lung cancer and FDA feedback supporting a clear Phase 3 path to potential accelerated approval in that patient population on Tuesday, November 10, 2026, at 7:30 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Webcast information

The webcast can be accessed under "Events and Presentations" on the Investors section of the Black Diamond website at www.blackdiamondtherapeutics.com. A replay of the webcast will be available following the completion of the event for a limited time.

About Silevertinib

Silevertinib is an investigational oral, covalent, brain-penetrant fourth-generation tyrosine kinase inhibitor (TKI) that selectively targets classical and more than 50 non-classical EGFR mutations in NSCLC. It is also designed to potently inhibit key EGFR alterations seen in GBM, including EGFRvIII, while avoiding the paradoxical EGFR activation reported with reversible TKIs. To date, over 200 patients with EGFRm NSCLC or EGFR-altered GBM have been treated with silevertinib.

In addition to the ongoing Phase 2 trial of silevertinib in patients with non-classical EGFRm NSCLC, the Company is also conducting a randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFRvIII-positive GBM (NCT07326566).

(Press release, Black Diamond Therapeutics, NOV 9, 2026, View Source [SID1234674504])